IL11 and cancer: Remarkably, the expression of interleukin 11 (IL11), one of the activators of STAT3 phosphorylation31 previously reported as a downstream effector of the TGF-beta pathway involved in cancer progression14, was significantly correlated with aFib-RS levels in CRC patients (Fig. 4a).